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INTRODUCTION
Cervical cancer is the second most prevalent cancer
in women around the world today and the most
common cancer in women that causes the death of
primarily young women. Based on the World
Health Organization (WHO) statistical data, there
are about 500,000 new cases and 250,000 deaths
each year.1 In general, higher incidences are
found in developing countries, and these
countries contribute 83% of reported cases
annually. Economically advantaged countries
have significantly lower cervical cancer rates and
add only 3.6% of new cancers. This incidence
disparity highlights successes achieved by cervical
Abstract
Objective: Cervical cancer is the second most prevalent cancer in
women around the world and the most common cancer in women
causing death. This study aims to analyze the connection between
infection of human papilloma virus (HPV) 16/18 and cervical
changes in the acceptors of Depot Medroxyprogesterone Acetate
(DMPA) Contraceptions and nonacceptors of Depot Medroxypro-
gesterone Acetate (DMPA) Contraceptions.
Methods: The research was conducted at the Public Service
Institution of Dr. Wahidin Sudirohusodo hospital, and private
midwife clinics for seven months from December 2015 to June 2016.
The research design is cross-sectional with. The samples were forty
acceptors of Depot Medroxyprogesterone Acetate (DMPA) and forty
non-acceptors of Depot Medroxyprogesterone Acetate (DMPA)
contraception. Prevalence of HPV 16/18 and cervical cytology
changes were examine using the polymerase chain reaction and
liquid base cervical cytology.
Results: The results showed there was no significant relationship
between long-term use of DMPA contraceptives with HPV 16 and 18.
There was no significant relationship between long-term use of
DMPA contraceptives with cervical cytology changes. There was no
significant relationship between HPV 16 and 18 infections with the
occurrence of cervical cytology changes in long-term use of DMPA
contraceptives.
Conclusion: The long-term use of DMPA contraceptive does not
increase the risk of HPV 16 and 18 infections. Also does not cause
cervical cytology changes that lead to cervical malignancy.
[Indones J Obstet Gynecol 2018; 6-2: 98-103]
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Abstrak
Tujuan: Kanker serviks merupakan kanker kedua terbanyak
pada wanita di seluruh dunia saat ini dan merupakan kankerterbanyak pada wanita yang menyebabkan kematian. Penelitian
ini bertujuan mengetahui hubungan antara infeksi human papi-
lloma virus 16/18 dan perubahan sitologi serviks pada akseptorkontrasepsi DMPA dibandingkan dengan non akseptor kontra-
sepsi DMPA.
Metode: Penelitian ini menggunakan rancangan potong lintang.
Penelitian ini dilakukan di BLU RS Dr. Wahidin Sudirohusodo, rumahsakit jejaring serta Bidan Praktek Swasta. Penelitian ini dilakukan
selama 7 bulan, yaitu mulai bulan Desember 2015- Juni 2016. Sampel
sebanyak 40 akseptor kontrasepsi DMPA dan 40 non akseptorkontrasepsi DMPA. Infeksi HPV 16/18 dan perubahan sitologi serviks
diperiksa melalui polymerase chain reaction dan Sitologi Serviks
Berbasis Cairan.
Hasil: Hasil penelitian menunjukkan tidak terdapat hubunganbermakna antara penggunaan kontrasepsi DMPA jangka panjang
dengan infeksi HPV 16 dan 18. Tidak terdapat hubungan bermakna
antara penggunaan kontrasepsi DMPA jangka panjang denganterjadinya perubahan sitologi serviks. Tidak terdapat hubungan
bermakna antara infeksi HPV 16 dan 18 dengan terjadinya
perubahan sitologi serviks pada penggunaan kontrasepsi DMPAjangka panjang.
Kesimpulan: Penggunaan kontrasepsi DMPA jangka panjang tidak
meningkatkan risiko terjadinya infeksi HPV 16 dan 18. Juga
tidak menyebabkan terjadinnya perubahan sitologi serviks yangmengarah kepada keganasan serviks.
[Maj Obstet Ginekol Indones 2018; 6-2: 98-103]
Kata kunci: infeksi HPV 16/18, kontrasepsi Depot Medroxypro-gesterone Acetate (DMPA) Contraceptions, perubahan sitologi
serviks
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cancer screening programs in which Papanicolaou
(Pap) smears are regularly obtained. In 2006, the
American Cancer Society estimated 9,710 new
cases and 3,700 deaths from this malignancy.2 Data
from the Ministry of Health in Indonesia, cervical
cancer and breast cancer still the highest preva-
lence among malignant gynecologic tumors. In
2013, the prevalence of cervical cancer was 0.8%,
and breast cancer is 0.5%.
HPV 16 and HPV 18 because this is a high-risk
HPV found in almost all cervical carcinoma. In the
United States and Europe, HPV 16 is the most
prevalent type found in approximately 50% of
cases, while types 18, 31 and 45 found in approxi-
mately 25 - 30% of cases.3
Progesterone contained in the Combined Oral
Contraceptives (COCs) causes depletion of squa-
mous epithelium thus it is more susceptible to HPV
infection.4 The relationship between the use of
DMPA contraceptive with HPV infection is
debatable. Research says that epithelial atrophy
becomes more susceptible to damage, so it be-
comes more susceptible to HPV infection. This may
explain that DMPA is positively associated with
oncogenic HPV infection. We found that the use of
DMPA results in depletion of the epithelium.5
Progesterone is previously considered as a
major candidate hormone in the cervical neoplastic
caused by the immunosuppressive effects and the
likely associated with HPV infection. Human
papilloma virus tends to infect the cells with
progesterone receptors. Both HPV 16 and 18
contain progesterone and glucocorticoid response
elements that increase the expression of oncogenic
HPV E6 and E7, which are considered crucial in
the transformation of cells with the gestagenic
stimuli.6
By knowing HPV as the primary cause of cervical
cancer, there is new development for the detection
of HPV as screening for uterine cervical carcinoma.
Therefore, HPV cannot be grown in culture, the
HPV DNA testing with the methods of molecular
biology is an accurate way to detect HPV infection
and HPV typing by PCR (Polymerase Chain
Reaction). In addition, early detection of cervical
cytological changes in contraceptive DMPA
acceptors is also important for the change in
cervical cytology is a risk factor for HPV infection.
For a screening of cervical cytological changes, the
most commonly used today is conventional Pap
smear. However, the conventional Pap smear has
the limitations, i.e., the false negative rate of
14 - 33% and two-thirds are caused by the process
of sampling or sample preparation. This leads to
inaccurate and equivocal diagnosis. Currently, the
major advanced screening technique is liquid-
based cytology. The transition from conventional
cytology to liquid-based cytology techniques
is due to the increased sample quality, repro-
ducibility, sensitivity, and specificity similar to
molecular testing.7
METHOD
This research was conducted at several hospitals
in Makassar, health centers and in Private
Practice Midwife (BPS) Hj. Markarmah. Prepara-
tions that have been taken from the research
subjects were sent to the Laboratory of Anato-
mical Pathology for liquid-based cervical cyto-
logy and the Laboratory of Microbiology for
PCR. The research began in December 2015 -
June 2016.
This was a cross-sectional study. The population
in this research was contraceptive DMPA
acceptors, and controls were those who did not
receive DMPA acceptors. The sample was injected
contraceptive DMPA acceptors, and the control
group were women who did not use progestin
injection hormonal contraceptive and met the
inclusion criteria and have signed the informed
consent to participate in the study.
All subjects who met the inclusion criteria were
taken in accordance with the estimated sample
size. Two examinations, i.e., PCR and liquid-based
cytology with LC-Prep, were done on the subjects.
Test results were recorded and then analyzed.
The data that have been collected and analyzed
were then processed by computer using SPSS
for windows. The statistical method used was
Bivariate Analysis Chi-square test and Fisher’s
exact.
RESULTS
The basic characteristics of the samples showed
that of the 80 research subjects involved, the
largest age group was 31 - 45 years old (57.5%)
with education level of more than nine years
(71.25%). Employment status of the research
subject was generally work (56.25%). The age at
the first coitus was generally 20 - 25 years
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(73.75%) with multiparity (63.75%). The length of
contraceptive use was over three years (52.5%)
with complaints of menstrual disorders (47.5%)
and a complaint of menstrual disorders with
vaginal discharge (50%). The research subjects
using contraceptive DMPA were mostly aged 31 -
45 years (60%), with education level of more than
nine years (55%). Employment status was not
working (55%). All contraceptive DMPA acceptors
were already married and the age at the first coitus
was 20 - 25 years (77.5%) with multiparity (80%).
The length of contraceptive use was mostly more
than three years (52.5%) with the majority of
complaints of menstrual disorders (97.5%). Based
on the results of Chi-square test and Fisher’s exact,
the homogeneous characteristics of the research
subjects obtained were age group, education,
occupation, marital status, age at the first coitus,
duration of contraceptive use and the type of
complaint (p> 0.05). (Appendix, Table 1).
HPV 16 infection based on PCR showed that the
research subjects who used contraceptive DMPA
had positive for HPV 16 of 1 people (2.5%) and
negative for HPV 16 of 39 people (97.5%). The
research subjects who did not use contraceptive
DMPA all had negative for HPV 16 of 40 people
(100%) (Appendix, Table 2).
Table 1. Characteristics of the Subjects
DMPA Contraceptive
Characteristics  Yes No Total
n % n % n %
Age (year)
20 - 30 16 40 18 45 34 42.5
31 - 45 24 60 22 55 46 57.7
Education Level
 9 year 22 55 1 2.5 23 28.75
> 9 year 18 45 39 97.5 57 71.25
Employment
Unemployment 18 45 27 67.5 45 56.25
Employment 22 55 13 32.5 35 43.75
Age first time coitus (year)
20 - 25 31 77.5 28 70 59 73.75
> 25 9 22.5 12 30 21 26.25
Parity
Nulli/Primipara 8 20 21 52.5 29 36.25
Multipara 32 80 19 47.5 51 63.75
Duration contraceptive use (year)
 3 19 47.5
> 3 21 52.5
Complain
No complain 1 2.5
Menstrual disorder 19 47.5
Menstrual disorder and flor albus 20 50
Table 2.  HPV 16 Infections
HPV 16
Subject Positive Negative Total p
n % n % n %
Contraceptive DMPA acceptors 1 2.5 39 97.5 40 100
Non Contraceptive DMPA acceptors 0 0 40 100 40 100 1.000
Total 1 1.2 79 98.8 80 100
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HPV 18 infection based on PCR showed that the
research subjects who used contraceptive DMPA
had positive for HPV 18 of 1 people (2.5%) and
negative for HPV 18 of 39 people (97.5%). The
research subjects who did not use contraceptive
DMPA all had negative for PCR 18 of 40 people
(100%). Fisher’s exact test results obtained by
value p = 1.000 (p> 0.05). It means there is no
relationship between hormonal contraceptive
use in combination with the incidence of HPV 18
infection (Appendix, Table 3).
Cervical cytology based on liquid-based cervical
cytology examination showed that the research
subjects who used contraceptive DMPA found
eight people who experienced cervical cytological
changes (20%). While for non-contraceptive DMPA
acceptors, there were six people who experienced
cervical cytological changes. Most of the samples
from both groups that did not experience changes
in cervical cytology were 66 people (82.5%)
(Appendix, Table 4).
DISCUSSION
This study shows that the use of contraceptive
DMPA has not been associated with HPV 16/18
infection and cervical cytological changes. This
study is conducted on contraceptive DMPA
acceptors for this contraceptive type is one risk
factor for cervical carcinoma with HPV infection.
In this study, we examined HPV 16 and HPV 18
because this is a high-risk HPV found in almost all
cervical carcinoma. In the United States and
Europe, HPV 16 is the most prevalent type found
in approximately 50% of cases, while types 18, 31
and 45 found in approximately 25 - 30% of cases.3
Based on the results of Chi-square test and
Fisher’s exact, the homogeneous characteristics of
the research subjects obtained were age group,
education, occupation, marital status, age at the
first coitus, duration of contraceptive use and the
type of complaint (p> 0.05). Most of the research
subjects had multiparity and used contraceptive
DMPA.
To determine the effect of contraceptive DMPA
to the HPV infection clearly, the risk factors that
may increase HPV infections such as first sexual
intercourse before age 20 years, parity more than
four, having multiple sexual partners and smoking
habits are excluded.
In this study, 80 subjects of the research found
one case of HPV 16 infection based on PCR on
contraceptive DMPA acceptor group with incidence
rates of 1.2% and one case of HPV 18 infection with
the incidence rate of 1.2%. There was no HPV
infection in the control group. After Fisher’s exact
test to determine the relationship between
contraceptive DMPA with HPV 16 and HPV 18
obtained results that were not statistically signifi-
cant. This is consistent with research conducted by
Morgan et al., which conducted follow up to 1,135
women (376 COC acceptors, 331 DMPA acceptors,
and 428 non- contraceptive acceptors) for 18
months. They found new HPV infection in 269
Table 3.  HPV 18 Infections
HPV 18
Subject Positive Negative Total p
n % n % n %
Contraceptive DMPA acceptors 1 2.5 39 97.5 40 100
Non Contraceptive DMPA acceptors 0 0 40 100 40 100 1.000
Total 1 1.2 79 100 80 100
Table 4.  Cervical Cytological Changes
cervical cytological changes
Subject Positive Negative Total p
n % n % n %
Contraceptive DMPA acceptors 8 20 32 80 40 100
Non Contraceptive DMPA acceptors 6 155 34 85 40 100 0.77
Total 14 17.5 66 82.5 80 100
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women and high-risk HPV infection in 157 women.
However, after adjusting for age, number of sexual
partners, new sexual partner, bacterial vaginosis
infection and duration of the use of COCs and
DMPA, the relation between the detection of new
HPV infection with the use of COCs reduced even
not statistically significant.4
The use of hormonal contraceptives such as
depomedroxyprogesterone acetate (DMPA) has
been associated with an increased risk of cervical
cancer and is considered as a co-factor in cervical
carcinogenesis. The increased risk of disease is
observed in women who use hormonal contra-
ceptives of long-term progesterone injection such
as DMPA. Progesterone contained in the Combined
Oral Contraceptives (COCs) causes depletion of
squamous epithelium thus it is more susceptible to
HPV infection.4 Based on the research results,
Tiffany G et al., stated that use of DMPA within
one year or more is related significantly to the
detection of oncogenic HPV.5
Progestin contained in contraceptive DMPA can
affect cervical cytology. The relationship between
the use of DMPA contraceptive with HPV infection
is debatable. Research says that epithelial
atrophy becomes more susceptible to damage,
so it becomes more susceptible to HPV infection.
This may explain that DMPA is positively
associated with oncogenic HPV infection. We
found that the use of DMPA results in depletion
of the epithelium.5
Progesterone is previously considered as a
major candidate hormone in the cervical neoplastic
caused by the immunosuppressive effects and
the likely associated with HPV infection. Human
papilloma virus tends to infect the cells with
progesterone receptors. Both HPV 16 and 18
contain progesterone and glucocorticoid response
elements that increase the expression of
oncogenic HPV E6 and E7, which are considered
crucial in the transformation of cells with the
gestagenic stimuli.6
In this study, of the 80 research subjects found
two cases of HPV infection, each infection with HPV
16 and HPV 18 in contraceptive DMPA acceptors.
On the samples with positive HPV 16 infection
found cervical cytological changes and on the
samples with positive HPV 18 infection also found
cervical cytological changes in the form of endo-
cervical cells undergoing squamous metaplasia and
found halo-perinuclear representation. Based on
Fisher’s exact test results, there was no association
between HPV 16/18 infection with cervical
cytological changes in the contraceptive DMPA
acceptors.
Normal cervical cytology can be found in the
latent phase of virus infection. In these circum-
stances, there are no lesions, but there is exposure
to the virus without causing infection. In this phase,
the virus cannot attach to the surface of cells or
penetrate cells since there are no or less cell
surface receptors specific for HPV. It can also occur
in cases where the virus has entered the cell but
has failed to do multiplication or no maturation of
viral particles. In this phase, the HPV virus can only
be detected with bio-molecular methods.
Genital HPV infection is very common, mostly
asymptomatic, does not cause a change in the
tissue and therefore is not detected on Pap smear.
The prevalence of HPV in cervical cytology in
women with normal Pap smears peaked at the age
of 20 - 24 years.
Not all women infected with human papil-
lomavirus (HPV) 16/18 have detectable levels of
anti  HPV-16/18 antibodies.  Women who
seroconvert develop low antibody levels and
seroconversion occurs within months and varies
among women. The slow and weak antibody
response generated by HPV infections could be
explained by its life-cycle in the host. HPV is shed
within intact cells lining mucosal surfaces, which
limits exposure of the host immune system to the
virus. HPV infected cells that undergo lysis (i.e.,
koilocytes) are shed to the environment and
infections do not produce viremia. Finally,
infections produce a limited load of HPV antigenic
proteins.8
Cervical cytological changes by HPV infection
are also associated with higher levels of viral load
in the host and the type of HPV. Previous studies
conducted on cervical cell of women with cervical
lesions (cancerous or pre-cancerous lesions) found
that the average level of viral load is higher in
women who are positive HPV.
This study has advantage and disadvantage. The
advantage of this study is that confounding factors
which can lead to a high incidence of HPV infection,
primarily high-risk HPV such as age at the first
coitus, parity, and number of sexual partners, are
removed. This is done so that the effect of
contraceptive DMPA against HPV infection,
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primarily high-risk HPV, can be seen clearly.
However, HPV DNA bio-molecular examination in
this study is devoted to the high-risk HPV types
16/18 so that other high-risk HPV types cannot be
detected.
CONCLUSION
The researcher concludes that out of 80 samples
found HPV 16 infection of 1.2% and HPV 18
infection of 1.2%. The role of contraceptive
DMPA against HPV 16/18 infection and cervical
cytological changes cannot be proven through
PCR and cervical cytology examination. In
addition, the relationship between HPV 16/18
infection with cervical cytology changes in
hormonal contraceptive DMPA acceptors has also
not been proven. Despite of this study found no
relationship between duration of use of
contraceptive DMPA with HPV infection and
cervical cytological changes, the two samples
infected with  HPV 16/18 are  found in
contraceptive DMPA acceptor groups that are also
experiencing cervical cytological changes. The
researcher suggests that further research on HPV
types 16/18 and other HPV types of hormonal
contraceptive DMPA acceptors is required. Further
research with greater samples to determine the
prevalence of HPV infection and cervical cytology
changes in contraceptive DMPA users is also
required.
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